Jiangsu Lianhuan Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Jiangsu Lianhuan Pharmaceutical Co Ltd cash flow-to-debt ratio. Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) has a Cash Flow-to-Debt Ratio of -0.01x as of September 2025, meaning its operating cash flow of CN¥-15.07 Million could theoretically repay 0% of its total liabilities (CN¥2.37 Billion) in one year. Check Jiangsu Lianhuan Pharmaceutical Co Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Jiangsu Lianhuan Pharmaceutical Co Ltd (2002–2024)
Cash flow-to-debt ratio of Jiangsu Lianhuan Pharmaceutical Co Ltd from 2002 to 2024. Historical debt coverage capacity for Jiangsu Lianhuan Pharmaceutical Co Ltd across 23 annual periods. Check 600513 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Jiangsu Lianhuan Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2002–2024)
Jiangsu Lianhuan Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2002 to 2024. Year-by-year debt coverage analysis for Jiangsu Lianhuan Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see Jiangsu Lianhuan Pharmaceutical Co Ltd cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.01x | CN¥10.77 Million | CN¥1.44 Billion | ▼ -93.8% |
| 2023 | 0.12x | CN¥160.70 Million | CN¥1.34 Billion | ▲ +22.5% |
| 2022 | 0.10x | CN¥127.59 Million | CN¥1.30 Billion | ▼ -23.9% |
| 2021 | 0.13x | CN¥138.34 Million | CN¥1.07 Billion | ▲ +21.5% |
| 2020 | 0.11x | CN¥91.94 Million | CN¥867.05 Million | ▲ +965.4% |
| 2019 | -0.01x | CN¥-9.87 Million | CN¥805.57 Million | ▲ +93.7% |
| 2018 | -0.19x | CN¥-92.00 Million | CN¥473.43 Million | ▼ -1629.9% |
| 2017 | 0.01x | CN¥3.64 Million | CN¥286.25 Million | ▼ -95.7% |
| 2016 | 0.29x | CN¥70.28 Million | CN¥239.03 Million | ▲ +6.8% |
| 2015 | 0.28x | CN¥62.12 Million | CN¥225.66 Million | ▼ -11.0% |
| 2014 | 0.31x | CN¥69.50 Million | CN¥224.71 Million | ▲ +105.8% |
| 2013 | 0.15x | CN¥37.17 Million | CN¥247.36 Million | ▼ -17.7% |
| 2012 | 0.18x | CN¥16.94 Million | CN¥92.79 Million | ▼ -30.8% |
| 2011 | 0.26x | CN¥24.00 Million | CN¥90.91 Million | ▲ +188.6% |
| 2010 | 0.09x | CN¥8.43 Million | CN¥92.13 Million | ▼ -40.8% |
| 2009 | 0.15x | CN¥13.83 Million | CN¥89.47 Million | ▼ -30.9% |
| 2008 | 0.22x | CN¥17.44 Million | CN¥77.98 Million | ▲ +144.1% |
| 2007 | 0.09x | CN¥8.03 Million | CN¥87.69 Million | ▼ -30.8% |
| 2006 | 0.13x | CN¥10.14 Million | CN¥76.64 Million | ▲ +71.2% |
| 2005 | 0.08x | CN¥3.82 Million | CN¥49.44 Million | ▲ +40.5% |
| 2004 | 0.06x | CN¥3.39 Million | CN¥61.63 Million | ▲ +119.6% |
| 2003 | -0.28x | CN¥-13.19 Million | CN¥46.99 Million | ▼ -159.9% |
| 2002 | 0.47x | CN¥19.22 Million | CN¥41.02 Million | — |